https://thewashingtonstandard.com/this-weird-cold-therapy-may-reduce-biomarkers-for-autoimmune-diseases/

Massimo Luciani - Uracil and vitamin B3 found in samples from asteroid Ryugu: https://english.tachyonbeam.com/2023/03/23/uracil-and-vitamin-b3-found-in-samples-from-asteroid-ryugu/ #Asteroid #Ryugu #Uracil #Niacin #VitaminB3 #Organics #Biomarkers #JAXA #Hayabusa2 #SampleReturn #Hokkaido #Astrobiology #Astronomy

Abstract 10712: Mrna COVID Vaccines Dramatically Increase Endothelial Inflammatory Markers and ACS Risk as Measured by the PULS Cardiac Test: a Warning A Peer Reviewed Journal BTW Doctor Vernon Coleman says that THIS STUDY being released shows that the #mRNA #Vaccine is a KILLER and anyone still injecting it into people is a #Murderer! Abstract Our group has been using the PLUS Cardiac Test (GD Biosciences, Inc, Irvine, CA) a clinically validated measurement of multiple protein biomarkers which generates a score predicting the 5 yr risk (percentage chance) of a new Acute Coronary Syndrome (ACS). The score is based on changes from the norm of multiple protein biomarkers including IL-16, a proinflammatory cytokine, soluble Fas, an inducer of apoptosis, and Hepatocyte Growth Factor (HGF)which serves as a marker for chemotaxis of T-cells into epithelium and cardiac tissue, among other markers. Elevation above the norm increases the PULS score, while decreases below the norm lowers the PULS score.The score has been measured every 3-6 months in our patient population for 8 years. Recently, with the advent of the mRNA COVID 19 vaccines (vac) by Moderna and Pfizer, dramatic changes in the PULS score became apparent in most patients.This report summarizes those results. A total of 566 pts, aged 28 to 97, M:F ratio 1:1 seen in a preventive cardiology practice had a new PULS test drawn from 2 to 10 weeks following the 2nd COVID shot and was compared to the previous PULS score drawn 3 to 5 months previously pre- shot. Baseline IL-16 increased from 35=/-20 above the norm to 82 =/- 75 above the norm post-vac; sFas increased from 22+/- 15 above the norm to 46=/-24 above the norm post-vac; HGF increased from 42+/-12 above the norm to 86+/-31 above the norm post-vac. These changes resulted in an increase of the PULS score from 11% 5 yr ACS risk to 25% 5 yr ACS risk. At the time of this report, these changes persist for at least 2.5 months post second dose of vac.We conclude that the mRNA vacs dramatically increase inflammation on the endothelium and T cell infiltration of cardiac muscle and may account for the observations of increased thrombosis, cardiomyopathy, and other vascular events following vaccination. https://www.ahajournals.org/doi/10.1161/circ.144.suppl_1.10712

Biomarkers Market- What will be the Short-term Impact of Coronavirus? Please visit: https://www.fortunebusinessinsights.com/biomarkers-market-102173

Coronavirus Outbreak: BiomarkerS Industry Fights Back with Well-defined Business Strategies https://www.fortunebusinessinsights.com/biomarkers-market-102173

Coronavirus Outbreak: BiomarkerS Industry Fights Back with Well-defined Business Strategies Click here to get the short-term and long-term impact of COVID-19 on this Biomarkers Market. Please visit: https://www.fortunebusinessinsights.com/biomarkers-market-102173

Cancer Biomarkers Market: Government-supported Awareness Programs will help Market Gain Traction, says Fortune Business Insights™ The global cancer biomarkers market size isforecastto reach USD 48.20billion by 2026 on account of the increasing popularity of personalized treatment for cancer worldwide. Biomarkers help to detect cancer at an early stage and facilitate noninvasive diagnosis at high-speed by utilizing different proteomic and genomic markers.As per a recently published report by Fortune Business insights™ titled, “Cancer Biomarkers Market Size, Share & Industry Analysis, By Cancer Type (Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer And Others), By Biomarker Type (PSA, HER-2, EGFR,KRAS, and others), By End User (Pharmaceutical & Biotechnology Companies, Diagnostics & Research Laboratories, Hospitals &Specialty Clinics, and Others), and Regional Forecast, 2019-2026,” the market size was USD 18.94 billion in 2018 and will exhibit a CAGR of 12.4% between 2019 and 2026. Request Sample PDF: https://www.fortunebusinessinsights.com/enquiry/sample/cancer-biomarkers-market-100630 Report Highlights The report offers a comprehensive overview of the market and its prime growth trajectories, such as drivers, restraints, challenges, and opportunities. It throws light on recent oncology biomarker market trends, key industry developments, and other interesting insights. The report emphasizes on the table of segmentation based on factors such as cancer type, biomarker type, end user, and geography. The report discusses the list of players operating in the market and the prime strategies adopted by them to gain a competitive edge in the market. For more information on the report, log on to the company website. The COVID-19 pandemic has caused huge losses for several companies by halting their manufacturing processes. The governments of various companies are persistently striving to prevent the transmission of coronavirus by promoting social distancing and sanitization measures. Our reports would help you in gaining more insights into the effects of COVID-19 on every market. Competitive Landscape: Substantial Investment in Research and Development of Novel Therapeutics to Escalate Market Competition Major companies in the Global Cancer Biomarkers Market are increasingly focusing on research and development activities to create new and innovative products to stay ahead of the competition. Staying on top of market trends & drivers is crucial for decision-makers to hold this emerging opportunity. The study provides information on market trends and development, drivers, capacities, technologies, and the changing investment structure of the Healthcare Industry. List of Key Cancer Biomarker MarketManufacturers: • Myriad RBM • Abbott • F. Hoffmann-La Roche Ltd. • BioVision Inc. • Thermo Fisher Scientific • R&D System • Bio-Rad Laboratories, Inc. • Sino Biological Inc. • CENTOGENE N.V. • Sino Biological Inc. • Axon Medchem

MicroRNAs in Human Cancers. George Calin is a principal investigator with the MD Anderson Cancer Center at the University of Texas. He specializes in how non-coding RNAs impact disease and virus mechanisms, specifically the role of microRNAs in human cancers. Listen to it here: https://bit.ly/33x5vxt Episode also available on Apple Podcasts: apple.co/30PvU9C . . . . #cancer #genes #genetics #Virus #RNA #microRNA #noncodingRNA #genomics #biomarkers #Findinggeniuspodcast #Healthpodcast #InternalMedicinepodcast #Biosciencespodcast

Searching for Alzheimer’s Biomarkers. David Wishart is a professor in the Departments of Biological Sciences and Computing Science at the University of Alberta (Wishart Lab). He works with bioinformatics software, nanobiology, and machine learning in healthcare to fine tune the use of biomarkers in diagnostics. Listen to it here: https://bit.ly/3nP2CkS Episode also available on Apple Podcasts: apple.co/30PvU9C . . . . #MachineLearning #BloodTest #Alzheimer #Computing #nanobiology #syntheticbiology #bioinformatics #metabolomics #Findinggeniuspodcast #Healthpodcast #InternalMedicinepodcast #Biosciencespodcast